How Leqembi’s Multi-Target Strategy Fights Alzheimer’s
For decades, Alzheimer's treatments could do little more than ease symptoms while the disease continued its relentless attack on the brain. Leqembi represents a different approach. Rather than simply treating the consequences of Alzheimer's, it targets the disease itself by attaching to harmful beta-amyloid proteins at multiple stages of their development—from the smallest, most toxic clusters to fully formed plaques. By interrupting this destructive process early and continuing to remove existing amyloid, Leqembi gives the brain a better opportunity to protect neurons, preserve memory, and maintain the connections that define who we are. Understanding why this matters begins with understanding how Alzheimer's damages the brain.
Leqembi or Kisunla
Every year, millions of people fear hearing the words, "It's Alzheimer's." Until recently, a diagnosis meant there was little that could be done except prepare for the future. Today, that has changed. For people diagnosed in the earliest stages of Alzheimer's disease, two groundbreaking treatments Leqembi and Kisunla offer new hope by slowing the progression of the disease. Choosing between them can feel overwhelming, especially when so much information is technical and constantly evolving. This article explains, in plain language, how these treatments work, how they differ, and why early diagnosis remains the single most important step in giving yourself the greatest opportunity to benefit from these remarkable advances.